41 Results for "

nu/nu.

" in MedChemExpress (MCE) Product Catalog:
Products (41)

41 Results for "nu/nu." in MCE Product Catalog:

44
44 Publications Verification
Cat. No.: HY-11006
CAS No.: 503468-95-9
Purity:  99.95%
Synonyms: nu7441
Target:  

DNA-PK

Research Areas:  

Cancer

KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-15719
CAS No.: 154447-35-5
Purity:  99.82%
Synonyms: LY293646
Target:  

DNA-PK Apoptosis

Research Areas:  

Cancer

NU 7026 (LY293646) is a novel specific DNA-PK inhibitor with IC50 of 0.23 μM, also inhibits PI3K with IC50 of 13 μM.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-110127
CAS No.: 1450644-28-6
Purity:  95.36%
Research Areas:  

Cancer

NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107419
CAS No.: 444723-13-1
Purity:  99.07%
Target:  

CDK Aurora Kinase

Research Areas:  

Cancer

NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
loading...
    loading...
Cat. No.: HY-18930
CAS No.: 2070015-09-5
Target:  

CDK

Research Areas:  

Cancer

NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related .
loading...
    loading...
Cat. No.: HY-15569
CAS No.: 444722-95-6
Purity:  99.23%
Target:  

CDK

Research Areas:  

Cancer

NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM) .
loading...
    loading...
Cat. No.: HY-151886
CAS No.: 2759420-43-2
NU223612 is a potent PROTAC (PROTACs) that degrades indoleamine 2,3-dioxygenase 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)) with a Kd of 640 nM. NU223612 potently degrades the IDO1 protein through CRBN-mediated proteasomal degradation. NU223612 is bound to CRBN with an affinity of 290 nM. NU223612 can cross the blood-brain barrier (BBB) .
loading...
    loading...
Cat. No.: HY-15044
CAS No.: 90417-38-2
Purity:  98.50%
Target:  

PARP

Research Areas:  

Neurological Disease Cancer

NU1025 is a potent PARP inhibitor with an IC50 of 400 nM and a Ki of 48 nM. NU1025 potentiates the cytotoxicity of ionizing radiation and anticancer agents. NU1025 has anti-cancer and neuroprotective activity .
loading...
    loading...
Cat. No.: HY-168529
Target:  

Myosin

Research Areas:  

Cancer

NU074381b (compound 5b) is a potent S100A4 inhibitor. NU074381b inhibits S100A4-NMII complex formation with an IC50 value of 0.48 µM. NU074381b inhibits cell proliferation and migration .
loading...
    loading...
Cat. No.: HY-13816
CAS No.: 220036-08-8
Purity:  99.04%
Target:  

CDK ATM/ATR

Research Areas:  

Cancer

NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with Kis of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .
loading...
    loading...
Cat. No.: HY-173066
CAS No.: 3048196-52-4
Research Areas:  

Cancer

NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-19316
CAS No.: 161058-83-9
Synonyms: O6-(Cyclohexylmethyl)guanine
Target:  

CDK

Research Areas:  

Cancer

NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based CDK inhibitor with IC50s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.
loading...
    loading...
Cat. No.: HY-125372
CAS No.: 16348-49-5
Purity:  99.85%
Synonyms: ABAO
Research Areas:  

Others

2-Amino benzamidoxime (ABAO) acts as a bioconjugation reagent precursor and a fluorescent probe precursor. 2-Amino benzamidoxime contains an aniline group for imine activation of aldehydes, as well as a nucleophilic group (Nu:) located at the ortho position of the amine, which is responsible for intramolecular cyclization. 2-Amino benzamidoxime reacts with glyoxal at the N-terminus of phage-displayed peptide libraries. Derivatives of 2-Amino benzamidoxime can be used for protein bioconjugation. Derivatives of 2-Amino benzamidoxime serve as fluorescent probes .\n



loading...
    loading...
Cat. No.: HY-A0149
CAS No.: 82-88-2
Synonyms: nu 1504
Target:  

Histamine Receptor

Research Areas:  

Neurological Disease

Phenindamine (Nu 1504) is an antihistamine .
loading...
    loading...
Cat. No.: HY-145427
CAS No.: 1257235-99-6
Target:  

DNA-PK

Research Areas:  

Cancer

NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
loading...
    loading...
Cat. No.: HY-15570
Target:  

CDK

Research Areas:  

Cancer

NU6301 is a NU6102 (a CDK2 inhibitor) (HY-15569) prodrug. NU6301 can rapidly generate NU6102 in mouse plasma. NU6301 has anticancer activity against endometrial cancer .
loading...
    loading...
Cat. No.: HY-14206
CAS No.: 188106-83-4
Target:  

PARP

Research Areas:  

Cancer

NU 1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor with a Ki of 6 nM. NU 1085 shows strong cytotoxicity to cancer cells (LC50 = 83-94 μM) and can enhance the anticancer effect of Temozolomide (HY-17364). NU 1085 can be used for the research of cancer, such as lung cancer .
loading...
    loading...
Cat. No.: HY-122038
CAS No.: 849723-20-2
Target:  

MDM-2/p53

Research Areas:  

Cancer

NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .
loading...
    loading...
Cat. No.: HY-116621
CAS No.: 503468-03-9
Target:  

DNA-PK

Research Areas:  

Cancer

NU-7163 is an ATP-competitive DNA-PK inhibitor (IC50=0.19 μM; Ki=24 nM). NU-7163 enhances the cytotoxicity of ionizing radiation against the HeLa human tumor cell line in vitro .
loading...
    loading...
Cat. No.: HY-118379
CAS No.: 156074-08-7
Target:  

Topoisomerase

Research Areas:  

Inflammation/Immunology

NU/ICRF 500 is a topo II catalytic inhibitor which increases CREST negative micronuclei in human lymphocytes .
loading...
    loading...